FDMT NASDAQ
4D Molecular Therapeutics, Inc.
1W: -5.5%
1M: -8.5%
3M: +7.5%
YTD: +86.8%
1Y: +56.6%
3Y: +5.0%
5Y: -61.1%
$13.67
-0.17 (-1.23%)
Weekly Expected Move ±7.2%
$12
$13
$14
$15
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (43)
4DMT Molecular enters phase 3 trial of 4D-150 for diabetic eye disease
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Squarepoint Ops LLC
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages
Engineers Gate Manager LP Boosts Position in 4D Molecular Therapeutics, Inc. $FDMT
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 7.3% Higher After Analyst Upgrade
Bank of New York Mellon Corp Purchases Shares of 152,337 4D Molecular Therapeutics, Inc. $FDMT
4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE
Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy?
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Bioventus (BVS) Q2 Earnings Meet Estimates
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts
Research Analysts Issue Forecasts for FDMT FY2030 Earnings
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics GAAP EPS of -$2.42 beats by $0.98
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Brokerages
4DMT Announces New Employment Inducement Grants
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Contrasting NLS Pharmaceutics (NASDAQ:NCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT)
4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,821.50 in Stock
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
4DMT Announces New Employment Inducement Grants
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript